The Alliance Select Investor Series - Biotechnology Portfolio [ASBTA] invests at least 65% of its assets in equity securities of biotechnology companies, with an emphasis on stocks of companies engaged in genomics-related product or service development. The Fund may also invest up to 25% of its assets in stocks of pharmaceutical companies.
“Genomics companies will revolutionize healthcare in the same way that the Internet has changed the technology sector", says Matthew Murray Portfolio Manager of Alliance Select Investor Series – Biotechnology Portfolio. “We believe demographic factors are causing an increased percentage of the US economy to be spent on healthcare. In addition, we believe that genomics will not only continue to speed up the creation of new drugs, but that it will also accelerate the growth in the portion of healthcare dollars going towards prescription drugs.”
In addition to 7 years experience as a biotechnology analyst, Matthew Murray holds a B.A. in Molecular Biology from U.C.L.A. and a Ph.D. in Biophysics from the University of California at Berkeley. He is a member of the Human Genome Organization and worked on the Human Genome Project for 4 years.
About Alliance Capital
Alliance Capital is a leading global investment management firm with $394 billion in assets under management as of March 31, 2000. Alliance Capital manages retirement assets for many of the largest U.S. public and private employee benefit plans (including 28 of the U.S. Fortune 100 companies), for public employee retirement funds in 31 out of the 50 U.S. states, and for foundations, endowments, banks, and insurance companies worldwide. Alliance Capital is also one of America’s largest mutual fund sponsors, with a diverse family of fund portfolios and approximately 5.8 million shareholder accounts.
Alliance Select Investor Series - Biotechnology Portfolio is a "non-diversified" fund and is subject to special risks which are described in the Fund's prospectus. Many biotechnology companies, particularly companies involved in genomics, have little or no operating history, unproven products and no established market for these products. Investments in these companies are subject to greater risks. The Portfolio can invest in securities denominated in currencies other than the U.S. dollar which may magnify these fluctuations due to changes in international exchange rates and the possibility of substantial volatility due to various factors including political and economic uncertainties throughout the world. These risks are more fully discussed in the Fund's prospectus.
For more complete information on any Alliance mutual fund, including investment objectives and policies, sales charges, expenses, risks and other matters of importance to prospective investors, call your financial representative or Alliance Capital at (800) 227-4618 for a current prospectus. Please read the prospectus carefully before investing or sending money.